Neurofilament light chain may be a potential biomarker for predicting progression of Alzheimer's disease
Serum NfL predicts disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer’s disease, as per a study reported in Nature Medicine. Serum neurofilament light chain (NfL) levels correlated with NfL levels in the cerebrospinal fluid (CSF) and were elevated at pre-symptomatic stages of familial Alzheimers disease There were noticeable changes in blood up to 16 years before the calculated onset of dementia symptoms
To continue reading this article
Continue reading your article with a eMediNexus account.